{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:20:24Z","timestamp":1790716824633,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,29]],"date-time":"2025-12-29T00:00:00Z","timestamp":1766966400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100007128","name":"Shaanxi Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2023-JC-JQ-64"],"award-info":[{"award-number":["2023-JC-JQ-64"]}],"id":[{"id":"10.13039\/501100007128","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GK202307003"],"award-info":[{"award-number":["GK202307003"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["GK202406013"],"award-info":[{"award-number":["GK202406013"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82201493"],"award-info":[{"award-number":["82201493"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471381"],"award-info":[{"award-number":["82471381"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82071348"],"award-info":[{"award-number":["82071348"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.celrep.2025.116913","type":"journal-article","created":{"date-parts":[[2026,2,2]],"date-time":"2026-02-02T18:54:55Z","timestamp":1770058495000},"page":"116913","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Activation status of astrocytes drives the MS\/NMOSD therapeutic paradox: Insights from IFNAR1 signaling"],"prefix":"10.1016","volume":"45","author":[{"given":"Luhang","family":"Dai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sitong","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jingqi","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoli","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochang","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luting","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1714-2318","authenticated-orcid":false,"given":"Yaping","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2025.116913_bib1","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41572-020-0214-9","article-title":"Neuromyelitis optica","volume":"6","author":"Jarius","year":"2020","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.celrep.2025.116913_bib2","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/s41582-021-00568-8","article-title":"Hope for patients with neuromyelitis optica spectrum disorders \u2014 from mechanisms to trials","volume":"17","author":"Pittock","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib3","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1038\/s41582-024-01014-1","article-title":"NMOSD and MOGAD: an evolving disease spectrum","volume":"20","author":"Uzawa","year":"2024","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib4","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-021-02249-1","article-title":"Neuromyelitis optica spectrum disorders: from pathophysiology to therapeutic strategies","volume":"18","author":"Carnero Contentti","year":"2021","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.celrep.2025.116913_bib5","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines7020042","article-title":"Neuromyelitis Optica Spectrum Disorder and Anti-MOG Syndromes","volume":"7","author":"Lana-Peixoto","year":"2019","journal-title":"Biomedicines"},{"key":"10.1016\/j.celrep.2025.116913_bib6","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1016\/S0140-6736(04)17551-X","article-title":"A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis","volume":"364","author":"Lennon","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.celrep.2025.116913_bib7","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.celrep.2025.116913_bib8","doi-asserted-by":"crossref","first-page":"1105","DOI":"10.1001\/jamaneurol.2023.2974","article-title":"Rapid Immunodot AQP4 Assay for Neuromyelitis Optica Spectrum Disorder","volume":"80","author":"Fu","year":"2023","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib9","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200124","article-title":"International Delphi Consensus on the Management of AQP4-IgG+ NMOSD","volume":"10","author":"Paul","year":"2023","journal-title":"Neurology Neuroimmunology & Neuroinflammation"},{"key":"10.1016\/j.celrep.2025.116913_bib10","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1212\/01.wnl.0000216139.44259.74","article-title":"Revised diagnostic criteria for neuromyelitis optica","volume":"66","author":"Wingerchuk","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.celrep.2025.116913_bib11","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1212\/WNL.0000000000002366","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"86","author":"Tan","year":"2016","journal-title":"Neurology"},{"key":"10.1016\/j.celrep.2025.116913_bib12","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1093\/brain\/awl371","article-title":"Pattern-specific loss of aquaporin-4 immunoreactivity distinguishes neuromyelitis optica from multiple sclerosis","volume":"130","author":"Roemer","year":"2007","journal-title":"Brain"},{"key":"10.1016\/j.celrep.2025.116913_bib13","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1212\/01.wnl.0000254502.87233.9a","article-title":"A secondary progressive clinical course is uncommon in neuromyelitis optica","volume":"68","author":"Wingerchuk","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.celrep.2025.116913_bib14","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.nicl.2017.06.019","article-title":"Cervical cord myelin water imaging shows degenerative changes over one year in multiple sclerosis but not neuromyelitis optica spectrum disorder","volume":"16","author":"Combes","year":"2017","journal-title":"Neuroimage. Clin."},{"key":"10.1016\/j.celrep.2025.116913_bib15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1093\/brain\/awac079","article-title":"A new form of axonal pathology in a spinal model of neuromyelitis optica","volume":"145","author":"Herwerth","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.celrep.2025.116913_bib16","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00281-022-00941-9","article-title":"Immuno-pathogenesis of neuromyelitis optica and emerging therapies","volume":"44","author":"Chihara","year":"2022","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.celrep.2025.116913_bib17","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S1474-4422(06)70333-7","article-title":"OSMS is NMO, but not MS: proven clinically and pathologically","volume":"5","author":"Weinshenker","year":"2006","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib18","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1038\/ncpneuro0764","article-title":"Mechanisms of Disease: aquaporin-4 antibodies in neuromyelitis optica","volume":"4","author":"Jarius","year":"2008","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22168638","article-title":"Treatment of Neuromyelitis Optica Spectrum Disorders","volume":"22","author":"Chan","year":"2021","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.celrep.2025.116913_bib20","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s00401-013-1172-z","article-title":"Involvement of antibody-dependent cell-mediated cytotoxicity in inflammatory demyelination in a mouse model of neuromyelitis optica","volume":"126","author":"Ratelade","year":"2013","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.celrep.2025.116913_bib21","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1002\/glia.22608","article-title":"Interferons in the central nervous system: A few instruments play many tunes","volume":"62","author":"Owens","year":"2014","journal-title":"Glia"},{"key":"10.1016\/j.celrep.2025.116913_bib22","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/glia.23938","article-title":"Type I interferon-activated microglia are critical for neuromyelitis optica pathology","volume":"69","author":"Wlodarczyk","year":"2021","journal-title":"Glia"},{"key":"10.1016\/j.celrep.2025.116913_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.578648","article-title":"Human Commensal Prevotella histicola Ameliorates Disease as Effectively as Interferon-Beta in the Experimental Autoimmune Encephalomyelitis","volume":"11","author":"Shahi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2025.116913_bib24","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1007\/s12325-014-0149-1","article-title":"Current Perspectives on Interferon Beta-1b for the Treatment of Multiple Sclerosis","volume":"31","author":"Marziniak","year":"2014","journal-title":"Adv. Ther."},{"key":"10.1016\/j.celrep.2025.116913_bib25","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.it.2011.03.008","article-title":"Interferon-\u03b2 exacerbates Th17-mediated inflammatory disease","volume":"32","author":"Axtell","year":"2011","journal-title":"Trends Immunol."},{"key":"10.1016\/j.celrep.2025.116913_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1001\/jama.2018.20588","article-title":"Association of Initial Disease-Modifying Therapy With Later Conversion to Secondary Progressive Multiple Sclerosis","volume":"321","author":"Brown","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.celrep.2025.116913_bib27","article-title":"Type I Interferon Signaling Augments Autoimmunity in Neuromyelitis Optica Spectrum Disorder","volume":"12","author":"Zhang","year":"2025","journal-title":"Adv. Sci."},{"key":"10.1016\/j.celrep.2025.116913_bib28","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1038\/nm.2110","article-title":"T helper type 1 and 17 cells determine efficacy of interferon-\u03b2 in multiple sclerosis and experimental encephalomyelitis","volume":"16","author":"Axtell","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.116913_bib29","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1038\/nrneurol.2014.141","article-title":"Treatment of neuromyelitis optica: state-of-the-art and emerging therapies","volume":"10","author":"Papadopoulos","year":"2014","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib30","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1093\/brain\/awad373","article-title":"Interferon-\u03b3 controls aquaporin 4-specific Th17 and B cells in neuromyelitis optica spectrum disorder","volume":"147","author":"Arellano","year":"2024","journal-title":"Brain"},{"key":"10.1016\/j.celrep.2025.116913_bib31","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1001\/archneurol.2010.188","article-title":"Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers","volume":"67","author":"Palace","year":"2010","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib32","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1177\/1352458512439439","article-title":"Does interferon beta treatment exacerbate neuromyelitis optica spectrum disorder?","volume":"18","author":"Kim","year":"2012","journal-title":"Mult. Scler."},{"key":"10.1016\/j.celrep.2025.116913_bib33","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1212\/WNL.0b013e3181f8832e","article-title":"IFN\u03b2-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum","volume":"75","author":"Shimizu","year":"2010","journal-title":"Neurology"},{"key":"10.1016\/j.celrep.2025.116913_bib34","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1111\/j.1468-1331.2009.02897.x","article-title":"Different responses to interferon beta-1b treatment in patients with neuromyelitis optica and multiple sclerosis","volume":"17","author":"Uzawa","year":"2010","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib35","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/nm.4106","article-title":"Type I interferons and microbial metabolites of tryptophan modulate astrocyte activity and central nervous system inflammation via the aryl hydrocarbon receptor","volume":"22","author":"Rothhammer","year":"2016","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.116913_bib36","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1038\/s41593-025-02072-4","article-title":"Astrocytic Ca2+ prevents synaptic depotentiation by limiting repetitive activity in dendrites during motor learning","volume":"11","author":"Lai","year":"2025","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.celrep.2025.116913_bib37","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.2165\/11204560-000000000-00000","article-title":"Glatiramer acetate: a review of its use in relapsing-remitting multiple sclerosis and in delaying the onset of clinically definite multiple sclerosis","volume":"70","author":"Carter","year":"2010","journal-title":"Drugs"},{"key":"10.1016\/j.celrep.2025.116913_bib38","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s40265-014-0212-x","article-title":"Teriflunomide and its mechanism of action in multiple sclerosis","volume":"74","author":"Bar-Or","year":"2014","journal-title":"Drugs"},{"key":"10.1016\/j.celrep.2025.116913_bib39","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-020-01874-6","article-title":"Tanshinone IIA alleviates brain damage in a mouse model of neuromyelitis optica spectrum disorder by inducing neutrophil apoptosis","volume":"17","author":"Gong","year":"2020","journal-title":"J. Neuroinflammation"},{"key":"10.1016\/j.celrep.2025.116913_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.117188","article-title":"Isoliquiritigenin alleviates experimental autoimmune encephalomyelitis by modulating inflammatory and neuroprotective reactive astrocytes","volume":"178","author":"Zhang","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"10.1016\/j.celrep.2025.116913_bib41","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1474-4422(18)30460-5","article-title":"Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"18","author":"Ciccarelli","year":"2019","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.679498","article-title":"IFN-\u03b2 Acts on Monocytes to Ameliorate CNS Autoimmunity by Inhibiting Proinflammatory Cross-Talk Between Monocytes and Th Cells","volume":"12","author":"Rasouli","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.celrep.2025.116913_bib43","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41577-022-00718-z","article-title":"The immunology of multiple sclerosis","volume":"22","author":"Attfield","year":"2022","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.celrep.2025.116913_bib44","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/nrneurol.2012.203","article-title":"B cells and antibodies in multiple sclerosis pathogenesis and therapy","volume":"8","author":"Krumbholz","year":"2012","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib45","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1111\/imm.12781","article-title":"Interferon-\u03b2 regulates dendritic cell activation and migration in experimental autoimmune encephalomyelitis","volume":"152","author":"Pennell","year":"2017","journal-title":"Immunology"},{"key":"10.1016\/j.celrep.2025.116913_bib46","article-title":"Experimental Neuromyelitis Optica Induces a Type I Interferon Signature in the Spinal Cord","volume":"11","author":"Aktas","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2025.116913_bib47","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib48","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/S1474-4422(22)00431-8","article-title":"Diagnosis of myelin oligodendrocyte glycoprotein antibody-associated disease: International MOGAD Panel proposed criteria","volume":"22","author":"Banwell","year":"2023","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.celrep.2025.116913_bib49","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.neuron.2020.08.012","article-title":"Astrocyte Crosstalk in CNS Inflammation","volume":"108","author":"Linnerbauer","year":"2020","journal-title":"Neuron"},{"key":"10.1016\/j.celrep.2025.116913_bib50","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/glia.21088","article-title":"Inhibition of reactive astrocytosis in established experimental autoimmune encephalomyelitis favors infiltration by myeloid cells over T cells and enhances severity of disease","volume":"59","author":"Toft-Hansen","year":"2010","journal-title":"Glia"},{"key":"10.1016\/j.celrep.2025.116913_bib51","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nm.3681","article-title":"Regulation of astrocyte activation by glycolipids drives chronic CNS inflammation","volume":"20","author":"Mayo","year":"2014","journal-title":"Nat. Med."},{"key":"10.1016\/j.celrep.2025.116913_bib52","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/j.bbi.2017.04.023","article-title":"Low expression of complement inhibitory protein CD59 contributes to humoral autoimmunity against astrocytes","volume":"65","author":"Wang","year":"2017","journal-title":"Brain Behav. Immun."},{"key":"10.1016\/j.celrep.2025.116913_bib53","doi-asserted-by":"crossref","first-page":"3471","DOI":"10.4049\/jimmunol.1600135","article-title":"CFHR1-Modified Neural Stem Cells Ameliorated Brain Injury in a Mouse Model of Neuromyelitis Optica Spectrum Disorders","volume":"197","author":"Shi","year":"2016","journal-title":"J. Immunol."},{"key":"10.1016\/j.celrep.2025.116913_bib54","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nature21029","article-title":"Neurotoxic reactive astrocytes are induced by activated microglia","volume":"541","author":"Liddelow","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2025.116913_bib55","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.neuron.2011.07.022","article-title":"Development of a Method for the Purification and Culture of Rodent Astrocytes","volume":"71","author":"Foo","year":"2011","journal-title":"Neuron"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725016857?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124725016857?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,25]],"date-time":"2026-04-25T05:07:05Z","timestamp":1777093625000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124725016857"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":55,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2211124725016857"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2025.116913","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Activation status of astrocytes drives the MS\/NMOSD therapeutic paradox: Insights from IFNAR1 signaling","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2025.116913","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"116913"}}